CD160 and non-small cell lung carcinoma: According to a human scRNA-seq dataset of non-small cell lung cancer (NSCLC)27, we found that the proportion of CD160+CD8+ T cells in total CD8+ T cells in the control samples was significantly higher compared to that in NSCLC samples (Fig. 3e), potentially linking the inadequacy of pulmonary CD160+CD8+ T cells to lung tumorigenicity.